Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Kim Arndt"'
Autor:
Kim Arndt, Robert Abraham, Steve Haney, Dennis Powell, Fuk-Wah Sum, Veronica Diesl, Max Follettie, Sreekala Mandiyan, Judy Lucas, Maria Gavriil, Yixian Zhang
TNFa reduced genes from IκBα Kinase Inhibitor IKI-1 Conferred Tumor Necrosis Factor α Sensitivity to Pancreatic Cancer Cells and a Xenograft Tumor Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25d41f7b8daf8b0448f33753eb68a6d4
https://doi.org/10.1158/0008-5472.22377033
https://doi.org/10.1158/0008-5472.22377033
Autor:
Kim Arndt, Robert Abraham, Steve Haney, Dennis Powell, Fuk-Wah Sum, Veronica Diesl, Max Follettie, Sreekala Mandiyan, Judy Lucas, Maria Gavriil, Yixian Zhang
Tumor necrosis factor α (TNFα) has been used to treat patients with certain tumor types. However, its antitumor activity has been undermined by the activation of IκBα kinase (IKK), which in turn activates nuclear factor-κB (NF-κB) to help cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17fc423cbc8dc42389380682cd8bf98f
https://doi.org/10.1158/0008-5472.c.6498408.v1
https://doi.org/10.1158/0008-5472.c.6498408.v1
Autor:
Kim Arndt, Robert Abraham, Steve Haney, Dennis Powell, Fuk-Wah Sum, Veronica Diesl, Max Follettie, Sreekala Mandiyan, Judy Lucas, Maria Gavriil, Yixian Zhang
Supplementary Table 1 from IκBα Kinase Inhibitor IKI-1 Conferred Tumor Necrosis Factor α Sensitivity to Pancreatic Cancer Cells and a Xenograft Tumor Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::298b9dce108d5092e36f4fb9459c9418
https://doi.org/10.1158/0008-5472.22377036.v1
https://doi.org/10.1158/0008-5472.22377036.v1
Autor:
Kim Arndt, Robert Abraham, Steve Haney, Dennis Powell, Fuk-Wah Sum, Veronica Diesl, Max Follettie, Sreekala Mandiyan, Judy Lucas, Maria Gavriil, Yixian Zhang
TNFa-induced genes from IκBα Kinase Inhibitor IKI-1 Conferred Tumor Necrosis Factor α Sensitivity to Pancreatic Cancer Cells and a Xenograft Tumor Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::313e24af0b951f05c9b9eee017d5334a
https://doi.org/10.1158/0008-5472.22377030.v1
https://doi.org/10.1158/0008-5472.22377030.v1
Autor:
Uudus Bayarsaikhan, Michael Klinge, Kim Arndt, Daniela Sauer, Choimaa Dulamsuren, Florian D. Schneider
Publikováno v:
Earth Surface Processes and Landforms. 46:1766-1782
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfa180abf95b3172e4e6eb2b598b8cf4
https://doi.org/10.1002/esp.5116
https://doi.org/10.1002/esp.5116
Autor:
Maximillian T. Follettie, David Fruhling, Joy Grant, James Ahn, Jeremy S. Myers, Wenyan Zhong, Benedikt Bosbach, Jadwiga Bienkowska, Kim Arndt, Brendan Veeneman, Ying Gao
Publikováno v:
Nucleic Acids Research
CRISPR/Cas9 functional genomic screens have emerged as essential tools in drug target discovery. However, the sensitivity of available genome-wide CRISPR libraries is impaired by guides which inefficiently abrogate gene function. While Cas9 cleavage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba346670bdaa286b5854bdd14d963590
https://pubmed.ncbi.nlm.nih.gov/32821942
https://pubmed.ncbi.nlm.nih.gov/32821942
Autor:
Peter Olson, Koleen Eisele, Zhou Zhu, Valeria Fantin, Danan Li, David J. Shields, John Chionis, Todd VanArsdale, Chaoting Liu, Jing Yuan, Nathan V. Lee, Kim Arndt
Publikováno v:
Cancer Research. 76:P3-06
Estrogen receptor positive breast cancers show frequent deregulation of Cyclin D-CDK4/6 signaling. Combining CDK4/6 inhibitors with hormonal therapies produces clinical benefit, supporting drug approval of the first CDK4/6 inhibitor, Palbociclib, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a128f397ebc56a1c2994b62ec4be8b3b
https://doi.org/10.1158/1538-7445.sabcs15-p3-06-01
https://doi.org/10.1158/1538-7445.sabcs15-p3-06-01
Autor:
Koleen Eisele, Holly M. Alley, Robert J. Crowder, Tina Primeau, Jin-Ping Lai, Kim Arndt, Shunqiang Li, Todd VanArsdale, Suzanne E. Wardell, Elizabeth Griffin, Stephen Dann, John D. Norris, Donald P. McDonnell, Matthew J. Ellis, Jieya Shao
Publikováno v:
Clinical Cancer Research. 21:5121-5130
Purpose: Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line therapy for the management of estrogen receptor (ESR1)–positive breast cancer. However, ESR1 mutations or other ligand-independent ESR1 activation mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33fba124c1ee6cc6eb36eec0eed871c4
https://doi.org/10.1158/1078-0432.ccr-15-0360
https://doi.org/10.1158/1078-0432.ccr-15-0360
Publikováno v:
Clinical Cancer Research. 21:2905-2910
Cancer cells bypass normal controls over mitotic cell-cycle progression to achieve a deregulated state of proliferation. The retinoblastoma tumor suppressor protein (pRb) governs a key cell-cycle checkpoint that normally prevents G1-phase cells from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815da12cd58842ab4ab1eb8b248c51ae
https://doi.org/10.1158/1078-0432.ccr-14-0816
https://doi.org/10.1158/1078-0432.ccr-14-0816
Autor:
Osvaldo Dos Santos, Inder Chaudhary, Kim Arndt, Judy Lucas, Veronica Diesl, Natasja Brooijmans, Aranapakam Mudumbai Venkatesan, Semiramis Ayral-Kaloustian, Kevin J. Curran, Max Follettie, Susan Quinn Dejoy, Lei Chen, Efren Guillermo Delos Santos, Christoph Martin Dehnhardt, Zecheng Chen, Rosanne Petersen, Tarek S. Mansour, Yi Geng
Publikováno v:
Journal of Medicinal Chemistry. 53:897-910
We are introducing a novel series of 2,4-diaminoquinazolines as beta-catenin/Tcf4 inhibitors which were identified by ligand-based design. Here we elucidate the SAR of this series and explain how we were able to improve key molecular properties such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71e05daac3bd05bde9e23c93510e3ae1
https://doi.org/10.1021/jm901370m
https://doi.org/10.1021/jm901370m